MX2019001255A - Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda. - Google Patents

Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.

Info

Publication number
MX2019001255A
MX2019001255A MX2019001255A MX2019001255A MX2019001255A MX 2019001255 A MX2019001255 A MX 2019001255A MX 2019001255 A MX2019001255 A MX 2019001255A MX 2019001255 A MX2019001255 A MX 2019001255A MX 2019001255 A MX2019001255 A MX 2019001255A
Authority
MX
Mexico
Prior art keywords
ameliorating
treating
lung injury
adamts13
preventing
Prior art date
Application number
MX2019001255A
Other languages
English (en)
Inventor
Ewenstein Bruce
Goldstein Brahm
Scheiflinger Friedrich
Majer Bernhard
Rossato Paolo
Turecek Marietta
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2019001255A publication Critical patent/MX2019001255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción proporciona composiciones y métodos para tratar, mejorar y/o prevenir una crisis vaso-oclusiva (VOC) en un sujeto que padece de enfermedad de células falciformes (SCD). La descripción también proporciona composiciones y métodos para tratar, mejorar, y/o prevenir lesión pulmonar en un sujeto que padece de o está en riesgo de padecer de lesión pulmonar aguda (ALI) y/o síndrome de insuficiencia respiratoria aguda (ARDS). La descripción proporciona una Desintegrina y Metaloproteinasa con motivo tipo 1 de Trombospondina, miembro-13 (ADAMTS13) o una composición que comprende ADAMTS13 para tratar, mejorar y/o prevenir la VOC, o para tratar, mejorar, y/o prevenir lesión pulmonar en un sujeto que padece de o está en riesgo de padecer de ALI y/o ARDS.
MX2019001255A 2016-08-04 2017-08-04 Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda. MX2019001255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371030P 2016-08-04 2016-08-04
PCT/US2017/045573 WO2018027169A1 (en) 2016-08-04 2017-08-04 Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

Publications (1)

Publication Number Publication Date
MX2019001255A true MX2019001255A (es) 2019-05-20

Family

ID=59650005

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001255A MX2019001255A (es) 2016-08-04 2017-08-04 Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
MX2023010126A MX2023010126A (es) 2016-08-04 2019-01-29 Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miebro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010126A MX2023010126A (es) 2016-08-04 2019-01-29 Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miebro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.

Country Status (13)

Country Link
US (2) US11191818B2 (es)
EP (1) EP3493830A1 (es)
JP (3) JP2019527689A (es)
KR (2) KR20230079461A (es)
CN (2) CN109789192B (es)
AU (2) AU2017307582C1 (es)
BR (1) BR112019002194A2 (es)
CA (1) CA3031740A1 (es)
EA (1) EA201990373A1 (es)
IL (1) IL264372B2 (es)
MX (2) MX2019001255A (es)
SG (1) SG11201900853SA (es)
WO (1) WO2018027169A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536633A (ja) * 2019-06-07 2022-08-18 武田薬品工業株式会社 鎌状赤血球症の治療のための組換えａｄａｍｔｓ１３の使用
CA3173709A1 (en) 2020-04-02 2021-10-07 Friedmund BACHMANN Adamts13 variant, compositions, and uses thereof
WO2022145536A1 (ko) * 2020-12-30 2022-07-07 경상대학교병원 급성 호흡 곤란 증후군 환자의 예후 예측을 위한 정보제공방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
AU2006257073B2 (en) * 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
WO2009140140A1 (en) * 2008-05-12 2009-11-19 Immune Disease Institute Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
CA2769361A1 (en) 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
KR20210054598A (ko) 2009-09-21 2021-05-13 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
BR112013000515B1 (pt) 2010-07-08 2021-11-03 Takeda Pharmaceutical Company Limited Método para produzir uma composição de fator von willebrand recombinante (rvwf)
WO2012120130A1 (en) * 2011-03-09 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods to characterize patients suffering from hemolysis
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Also Published As

Publication number Publication date
CN109789192B (zh) 2023-04-07
CN109789192A (zh) 2019-05-21
US20220047688A1 (en) 2022-02-17
JP2022113855A (ja) 2022-08-04
AU2021200572A1 (en) 2021-03-04
JP7204030B2 (ja) 2023-01-13
AU2017307582A1 (en) 2019-02-07
JP2023026513A (ja) 2023-02-24
SG11201900853SA (en) 2019-02-27
KR102537083B1 (ko) 2023-05-25
AU2021200572B2 (en) 2023-12-07
IL264372B2 (en) 2024-05-01
EA201990373A1 (ru) 2019-07-31
US11191818B2 (en) 2021-12-07
MX2023010126A (es) 2023-09-06
CN116159130A (zh) 2023-05-26
IL264372B1 (en) 2024-01-01
CA3031740A1 (en) 2018-02-08
KR20230079461A (ko) 2023-06-07
AU2017307582C1 (en) 2021-05-06
US20190336588A1 (en) 2019-11-07
BR112019002194A2 (pt) 2019-05-21
WO2018027169A1 (en) 2018-02-08
IL264372A (en) 2019-02-28
JP2019527689A (ja) 2019-10-03
KR20190045196A (ko) 2019-05-02
EP3493830A1 (en) 2019-06-12
AU2017307582B2 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
SA519410164B1 (ar) (pkr) تركيبات البيرولوبيرول بوصفها منشطات كينازُ البيروفات
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX2023010126A (es) Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miebro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
MX2022005015A (es) Nebulizador, dispositivo indicador y recipiente.
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
MY198202A (en) Container containing a nicotine solution
MX2016013635A (es) Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
CA186761S (en) Tire
WO2015026494A3 (en) Methods for treating tissue fibrosis
MX2016012248A (es) Composiciones para el tratamiento de autodigestion.
MX2016008283A (es) Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis.
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
GB2500128A (en) Colonoscopy-preparation
MX2014016121A (es) Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
MX350201B (es) Composiciones oftalmicas con ceras alcoxiladas naturales.
MX2017007130A (es) Metodos para el tratamiento de la desregulacion del mejorador de la cadena ligera kappa del factor nuclear de las celulas b activadas (nf-kb) en un organismo hospedero que tenga la necesidad del mismo usando composiciones de la membrana de la cascara del huevo.
CO2017004922A2 (es) Hoja de acero para tapa corona, método de fabricarla, y tapa corona
WO2015134631A3 (en) Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy
MX2017007492A (es) Prevención y tratamiento de condiciones inflamatorias.
黄新忠 Protective effect of resveratrol on 5/6 nephrectomized rats and its mechanism